Grace Science
San Francisco
About Grace Science
Grace Science is a developer of small molecule inhibitors of NGLY1 to treat various forms of cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.0M
- Funding stage: Seed
- Last round: Seed (Feb 2017)
- Website: gracescience.com
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/grace-science-112357 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.